Welcome to our dedicated page for Sutro Biopharma news (Ticker: STRO), a resource for investors and traders seeking the latest updates and insights on Sutro Biopharma stock.
Sutro Biopharma, Inc. (NASDAQ: STRO) is a clinical-stage oncology company developing next-generation antibody-drug conjugates (ADCs) using a proprietary cell-free platform. The STRO news page on Stock Titan aggregates company announcements, scientific updates, and regulatory disclosures so readers can follow how Sutro’s ADC pipeline and corporate strategy evolve over time.
News about Sutro frequently covers pipeline milestones, such as the initiation of a Phase 1 trial for STRO-004, a tissue factor–targeting exatecan ADC in TF-expressing solid tumors, and preclinical progress for programs like STRO-006 and the dual-payload candidate STRO-227. The company also issues updates on collaborations, including its work with Astellas on dual-payload immunostimulatory ADCs, and presentations at major scientific meetings like the World ADC Conference and the Society for Immunotherapy of Cancer (SITC) Annual Meeting.
Investors and observers will find corporate and financial communications here as well, including quarterly financial results, details of organizational restructuring aimed at extending the company’s cash runway, and information about actions related to its Nasdaq listing status, such as the 1-for-10 reverse stock split and subsequent confirmation of regained compliance with the minimum bid price requirement.
In addition, Sutro regularly announces participation in healthcare and investor conferences, virtual R&D days, and other events where management discusses the ADC platform, single- and dual-payload programs, and near- and long-term priorities. Bookmark this page to access a consolidated view of Sutro Biopharma’s latest press releases, scientific highlights, and market-facing updates related to its oncology-focused ADC pipeline.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Sutro Biopharma (NASDAQ: STRO) presented expanded preclinical data for its ROR1-targeting antibody-drug conjugate (ADC), STRO-003, at the AACR Annual Meeting 2023 in Orlando. This next-generation ADC demonstrated significant anti-tumor activity and immune-modulating effects in preclinical models, suggesting its ability to enhance checkpoint blockade therapy. The promising results indicate the potential of STRO-003 in treating immunogenically cold solid tumors, particularly in non-small cell lung cancer and triple-negative breast cancer. Sutro is preparing for IND-enabling studies of STRO-003, expected to complete in Q1 2024. The detailed findings will be accessible on the company’s website following the presentation.
Sutro Biopharma (STRO) announced plans to start a Phase 2/3 study for luvelta in platinum-resistant ovarian cancer in Q2 2023. The company reported a revenue of $67.8 million for 2022, an increase from $61.9 million in 2021, primarily from partnerships with Merck, Astellas, and others. Operating expenses rose to $196.7 million, influenced by higher R&D costs. As of the end of 2022, Sutro had cash and investments totaling $302.3 million, ensuring a cash runway into the second half of 2024. Notably, the company has also expanded its collaboration with Vaxcyte, securing significant upfront and potential future payments.
Sutro Biopharma announced the appointment of Anne Borgman, M.D., as Chief Medical Officer, with a compensation package that includes 175,000 stock options and 150,000 restricted stock units (RSUs). This compensation was approved by the Compensation Committee on March 1, 2023, to encourage employee acceptance. The RSUs and options are tied to Sutro's 2021 Equity Inducement Plan, with vesting conditions over a four-year period. Sutro is focused on developing novel antibody drug conjugates for oncology, with two products in clinical studies and collaborations with major pharmaceutical companies.
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage oncology company, will have CEO Bill Newell participate in an Ovarian Cancer panel at the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 9:10 a.m. ET in Boston, MA. The event will be accessible via the company's website, with a replay available for 30 days post-event.
Sutro is focused on developing site-specific and novel-format antibody drug conjugates (ADCs), with two ADCs currently in clinical trials for ovarian and endometrial cancers. The company collaborates with major pharmaceutical firms on various ADC projects aimed at treating multiple cancers.
FAQ
What is the current stock price of Sutro Biopharma (STRO)?
What is the market cap of Sutro Biopharma (STRO)?
